Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.660
-0.050 (-2.92%)
Apr 14, 2025, 12:31 PM EDT - Market open

Rein Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
13.8611.369.689.69.33
Upgrade
Research & Development
14.253.9917.9717.0111.17
Upgrade
Operating Expenses
28.1115.3527.6526.6120.5
Upgrade
Operating Income
-28.11-15.35-27.65-26.61-20.5
Upgrade
Interest & Investment Income
0.70.6---
Upgrade
Other Non Operating Income (Expenses)
-0.02-0.090.32-0.010.08
Upgrade
EBT Excluding Unusual Items
-27.43-14.84-27.33-26.62-20.42
Upgrade
Merger & Restructuring Charges
--0.93---
Upgrade
Gain (Loss) on Sale of Assets
-0.04-0.070.09
Upgrade
Asset Writedown
-37----
Upgrade
Other Unusual Items
---0.39-0.82
Upgrade
Pretax Income
-64.43-15.73-27.33-26.16-21.16
Upgrade
Income Tax Expense
-1.54----
Upgrade
Net Income
-62.88-15.73-27.33-26.16-21.16
Upgrade
Net Income to Common
-62.88-15.73-27.33-26.16-21.16
Upgrade
Shares Outstanding (Basic)
185542
Upgrade
Shares Outstanding (Diluted)
185542
Upgrade
Shares Change (YoY)
290.09%1.31%2.23%154.70%42.11%
Upgrade
EPS (Basic)
-3.51-3.42-6.02-5.89-12.14
Upgrade
EPS (Diluted)
-3.51-3.42-6.02-5.89-12.14
Upgrade
Free Cash Flow
-22.29-19.81-24.87-23.91-20.48
Upgrade
Free Cash Flow Per Share
-1.24-4.31-5.48-5.38-11.75
Upgrade
EBITDA
-28.05-15.23-27.48-26.48-20.33
Upgrade
D&A For EBITDA
0.060.120.170.120.16
Upgrade
EBIT
-28.11-15.35-27.65-26.61-20.5
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q